Cancer
DESTINY-BTC01
Hepatology
DESTINY-Biliary Tract Cancer-01: A Phase 3 Study of Trastuzumab Deruxtecan (T-DXd) and Rilvegostomig versus Standard-of-Care Gemcitabine, Cisplatin, and Durvalumab for First Line Locally Advanced or Metastatic HER2-expressing Biliary Tract Cancer
Contact Research Team:
[email protected]
Site principal investigator:
Osama MoSalem, MD
Learn more about this study:
NCT06467357